Table 1:
Baseline characteristics
| N | % | N | % | ||
|---|---|---|---|---|---|
| Total | 606 | 100 | Number of Prior Treatment* | ||
| Age | Median (range) | 3 (1, 10) | |||
| Median (range) | 58 (26, 73) | Donor Type | |||
| < 40 | 12 | 2 | HLA-identical sibling | 225 | 37.1 |
| 40–49 | 71 | 11.7 | 8/8 matched unrelated | 319 | 52.6 |
| 50–59 | 272 | 44.9 | 7/8 matched unrelated | 62 | 10.2 |
| 60–69 | 233 | 38.5 | D-R Sex Match | ||
| ≥ 70 | 18 | 3 | M-M | 273 | 45.1 |
| Patient Sex | M-F | 93 | 15.4 | ||
| Male | 438 | 72.3 | F-M | 131 | 21.6 |
| Female | 168 | 27.7 | F-F | 60 | 9.9 |
| KPS | UNK | 49 | 8.1 | ||
| 90–100 | 415 | 68.5 | D-R CMV Serology | ||
| < 90 | 172 | 28.4 | +/+ | 147 | 24.3 |
| UNK | 19 | 3.1 | +/− | 66 | 10.9 |
| HCT Comorbidity Score | −/+ | 173 | 28.6 | ||
| 0 | 242 | 39.9 | −/− | 168 | 27.7 |
| 1 | 109 | 18 | UNK | 52 | 8.6 |
| 2 | 77 | 12.7 | Graft Source | ||
| ≥3 | 177 | 29.2 | BM | 11 | 1.8 |
| UNK | 1 | 0.2 | PBSC | 594 | 98 |
| LDH (U/L) | UNK | 1 | 0.2 | ||
| Median (range) | 214 (2.4, 2738) | GVHD Prophylaxis | |||
| Normal | 377 | 62.2 | CI + MTX ± other(s) | 280 | 46.2 |
| Elevated | 208 | 34.3 | CI ± other(s) | 313 | 51.7 |
| UNK | 21 | 3.5 | Other | 11 | 1.8 |
| Lymphocyte Count (/μL) | UNK | 2 | 0.3 | ||
| Median (range) | 0.8 (0, 177) | Conditioing Regimen | |||
| ≤ 2000/μL | 449 | 74.1 | RIC | 324 | 53.5 |
| > 2000/μL | 142 | 23.4 | TBI±Other | 35 | |
| UNK | 15 | 2.5 | Flu/Bu±Other | 87 | |
| WBC Count (× 109/L) | Flu/Mel±Other | 88 | |||
| Median (range) | 3.6 (0, 204) | Other | 4 | ||
| < 2 | 84 | 13.9 | NST | 282 | 46.5 |
| 10-Feb | 448 | 73.9 | TBI±Other | 174 | |
| > 10 | 71 | 11.7 | Flu±Other | 52 | |
| UNK | 3 | 0.5 | Other | 56 | |
| Disease Status at HCT | Cytogenetic Abnormality** | ||||
| CR | 78 | 12.9 | Del(13q) | 167 | 35.6 |
| PR | 308 | 50.8 | Trisomy 12 | 66 | 14.1 |
| Nodal PR | 14 | 2.3 | Del(11q) | 108 | 23 |
| SD/PD/Relapse | 197 | 32.5 | Del(17p) | 151 | 32.2 |
| UNK | 9 | 1.5 | Normal | 116 | 24.7 |
| Time from Diagnosis to HCT | Complex 3,4 | 73 | 15.6 | ||
| < 3 yrs | 187 | 30.9 | Complex 5 | 55 | 11.7 |
| 3–6 yrs | 180 | 29.7 | UNK | 137 | 22.6 |
| ≥ 6 yrs | 239 | 39.4 | |||
| UNK | |||||
278 patients have missing information.
some patients fall into multiple categories.
UNK: unknown. KPS: Karnofsky Performance Score. LDH: lactate dehydrogenase. WBC: white blood cell count. CR: complete remission. PR: partial remission. SD: stable disease. PD: progressive disease. D-R: donor-recipient. M-M: male donor & male recipient. M-F: male donor & female recipient. F-M: female donor & male recipient. F-F: female donor & female recipient.BM: bone marrow. PBSC: peripheral blood stem cell. GVHD: graft-versus-host disease. CI: calcineurin inhibitor. MTX: methotrexate. RIC: reduced intensity conditioning. NST:Non-myeloablative conditioning. TBI: total body irradiation. Flu: fludarabine. Mel: Melphalan. TLI: total lymphoid irradiation. Complex 3,4: 3 or 4 cytogenetic abnormalities. Complex 5: 5 or more cytogenetic abnormalities.